Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS research · 2024-06-27

Clinical Trial Update: L218CAR19 in Patients With Relapsed/Refractory B-cell Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating L218CAR19 in relapsed or refractory B-cell lymphoma, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • L218CAR19

Snippet

Sponsor: Henan Cancer Hospital | Conditions: Relapsed/Refractory B-cell Lymphomas | Phase 1 | Status: RECRUITING